Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 118,932

Document Document Title
WO/2016/183425A1
The invention relates to a micro-encapsulation system for immobilizing mesenchymal stem cells (MSCs), methods for delivery of encapsulated MSCs into the central nervous system, and use of the encapsulated cells as cellular transplantatio...  
WO/2016/181945A1
The purpose of the present invention is to provide a novel composition and solvent for facilitating the production of a brain-derived neurotrophic factor (BDNF) and a method for facilitating the production of BDNF. According to the prese...  
WO/2016/180870A1
The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.  
WO/2016/180981A1
The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl) carbonyl] indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof and its therapeutic uses in the treatment of neurodegenerative disorders, i...  
WO/2016/180472A1
A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune di...  
WO/2016/182036A1
The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemot...  
WO/2016/180247A1
The present invention relates to a bicyclic compound used as an Lp-PLA2 inhibitor, a preparation method and pharmaceutical use thereof, and a pharmaceutical composition containing the compound. The structure of the bicyclic compound is s...  
WO/2016/180879A1
The present disclosure relates to a dopamine stabilizing agent and an anti-depressive agent for use in the treatment of disorders characterized by debilitating fatigue, such as myalgic encephalomyelitis (ME)/Chronic fatigue syndrome (CFS...  
WO/2016/183244A1
This disclosure is directed to a method of treating dependency on an opioid drug, including acute and post-acute withdrawal symptoms, comprising treating an opioid-dependent patient with noribogaine, noribogaine derivative, or pharmaceut...  
WO/2016/182840A1
The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of th...  
WO/2016/179566A1
The present application relates to new uses of 5-HT6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-pip...  
WO/2016/179217A1
Compositions and methods involving the co- application of a thrombolytic drug and a metal ion chelator are described.  
WO/2016/179481A1
Methods and compositions for treating a lysosomal movement associated disease in an animal, in which the position of lysosomes can influence disease progression, comprising administering an effective amount of a first lysosome migration ...  
WO/2016/177840A1
The present invention relates to a combination therapy comprising the use of riboflavin and oxaloacetate. Specifically, it is directed to new compositions, pharmaceutical compositions, kits of parts and methods for treating ischemic stro...  
WO/2016/177340A1
The present invention relates to bicyclic substituted benzene sulfonamide derivative, and the preparation method and pharmaceutical use thereof. In particular, disclosed in the present invention are the compound of formula (I) or a pharm...  
WO/2016/179398A1
Isoform-selective lysine deacetylase inhibitors are described. Inhibitors of the lysine deacetylase enzyme are useful as antitumor drugs and for treating addiction, asthma, cardio-vascular disease, immunosuppression, neurodegenerative di...  
WO/2016/179497A1
The present invention is directed, in part, to the treatment of a subject having a neurodegenerative disorder, such as Parkinson's disease (PD), by providing glucocerebrosidase enzyme. The enzyme may be provided, e.g., through gene thera...  
WO/2016/179252A1
The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an a...  
WO/2016/179569A1
The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination...  
WO/2016/173710A1
The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to spiro-isoquinoline-3,4'-piperidine compounds having this pharmacological activity, to processes of prepa...  
WO/2016/176177A1
Provided in some embodiments are compounds herein. Also provided in some embodiments are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight g...  
WO/2016/173425A1
This present invention relates to a glucopyranosyl derivative as sodium dependent glucose cotransporters (SGLTs) inhibitor, preparation processes thereof, and pharmaceutical uses thereof, pharmaceutical compositions containing the compou...  
WO/2016/176457A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [Formula should be inserted here] Also provided herein are pharmaceutical compositions, comprising compounds of Formula (...  
WO/2016/175240A1
Provided is an external agent for treating hyperhidrosis, said external agent comprising water, an anticholinergic and one or more salts selected from the group consisting of a lactate, tartrate, acetate and phosphate. This external agen...  
WO/2016/174188A1
The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2016/172855A1
Provided is a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method comprises the following steps of (1) formulating a Glatiramer acetate solution to be tested; (2) subjecting the sample to be t...  
WO/2016/176500A1
Preparations comprising an enriched population of extracellular vesicles (nEVs) having a negatively charged surface, and that are CD81+ and CD9-, are provided. Improved processes and methods for producing an enriched population of nEVs f...  
WO/2016/176449A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds o...  
WO/2016/176571A1
The present invention relates to compounds of Formula (la) and pharmaceutical compositions thereof that modulate the activity of GPR52. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods us...  
WO/2016/172952A1
Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIIIα inhibitor to treat Alzheimer's disease. Further, also provided is a method for screening a drug treating Alzheimer's disease by whether A...  
WO/2016/176437A1
Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive perform...  
WO/2016/174661A1
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.  
WO/2016/175646A1
The invention relates to a novel method for producing a nutraceutical amaranth formulation from whole amaranth grain. The resulting nutraceutical amaranth formulation has unique properties that can be used to solve problems of particular...  
WO/2016/176118A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.  
WO/2016/175236A1
The present invention addresses the problem of obtaining an anti-repulsive guidance molecule a (RGMa) antibody which has a high binding activity and few side effects and can be used as a medicine for preventing, treating, or preventing t...  
WO/2016/176460A1
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formu...  
WO/2016/176562A1
Provided herein are compounds and pharmaceutical compositions comprising EphA4 inhibitors. The EphA4 inhibitors and compositions thereof are useful for the treatment of ALS.  
WO/2016/174496A1
The invention includes a new class of radiolabeled compounds of formula I able to bind P-glycoprotein with high affinity and selectivity. The protein prevents accumulation in the brain of a wide range of drugs and, changes in P-gp expres...  
WO/2016/169028A1
The present invention provides three novel conotoxin peptides, namely κ-CPTx-btl06, κ-CPTx-btl07 and κ-CPTx-btl08, amino acid sequences thereof being shown as SEQ ID NO: 1, 2 and 3 respectively. The present invention also relates to p...  
WO/2016/171248A1
Provided is a compound that possibly has an orexin receptor antagonist activity and, therefore, is expected to be useful as a medicine for preventing or treating sleep disorder, depression, anxiety disorder, panic disorder, integration d...  
WO/2016/172437A2
In accordance with one or more embodiments, the present invention provides a compound of formulas I, II, and III, for use in methods of inhibition of PBX1-DNA interaction in a mammalian cell or population of cells, and for use in the tre...  
WO/2016/169421A1
The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (I), a pr...  
WO/2016/169453A1
A nerve growth factor composition and a powder injection. The composition consists of a nerve growth factor, a stabilizer, a pH buffer, and water. The stabilizer is one of sorbierite, dextran, trehalose, raffinose and mannitol. The use o...  
WO/2016/169902A1
The present invention relates to compounds of formula (I), wherein R1' is CH3 R1' is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1, and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethy...  
WO/2016/169698A1
The present invention relates to a compound reducing microtubule detyrosination in axonal tips selected from the group consisting of tubulin carboxypeptidase inhibitors and tubulin tyrosine ligase activators and combinations thereof for ...  
WO/2016/171181A1
Provided are fused pyrazole derivatives and pharmaceutically acceptable salts thereof that act at high selectivity on dopamine D4 receptors and are useful as agents for the treatment of attention deficit-hyperactivity disorder and the li...  
WO/2016/170501A1
A new therapeutic use of botulinum neurotoxin serotype A (Bont/A) is described, therapeutic treatment of paralysis caused by spinal cord injury.  
WO/2016/171249A1
Provided is the compound represented by formula (I) (in the formula, Y1 is O or the like; Z1 is, C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently hydrogen atoms or the like; R1 is a s...  
WO/2016/169663A1
Crystalline salts of 7,8-Didehydro-4,5 alpha-epoxy-17-methylmorphinan-3,6 alpha-diol sulfate(2:1), i.e. of morphine sulphate, are disclosed and four polymorphic forms of these salts are reported. The invention further relates to a pharma...  
WO/2016/169455A1
A nerve growth factor composition and a powder injection. The nerve growth factor composition consists of a nerve growth factor, a stabilizer, a supporting agent, a pH buffer, and water. The stabilizer is arginine, glutamic acid, glycine...  

Matches 51 - 100 out of 118,932